<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ivanenkov YA</submitter><funding>Russian Science Foundation</funding><pagination>1325</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9919490</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(3)</volume><pubmed_abstract>Novel variously substituted thiohydantoin-based &lt;i>dispiro&lt;/i>-indolinones were prepared using a regio- and diastereoselective synthetic route from 5-arylidene-2-thiohydantoins, isatines, and sarcosine. The obtained molecules were subsequently evaluated in vitro against the cancer cell lines LNCaP, PC3, HCT&lt;sup>wt&lt;/sup>, and HCT&lt;sup>(-/-)&lt;/sup>. Several compounds demonstrated a relatively high cytotoxic activity vs. LNCaP cells (IC&lt;sub>50&lt;/sub> = 1.2-3.5 µM) and a reasonable selectivity index (SI = 3-10). Confocal microscopy revealed that the conjugate of propargyl-substituted &lt;i>dispiro&lt;/i>-indolinone with the fluorescent dye Sulfo-Cy5-azide was mainly localized in the cytoplasm of HEK293 cells. P388-inoculated mice and HCT116-xenograft BALB/c nude mice were used to evaluate the anticancer activity of compound &lt;b>29&lt;/b> in vivo. Particularly, the TGRI value for the P388 model was 93% at the final control timepoint. No mortality was registered among the population up to day 31 of the study. In the HCT116 xenograft model, the compound (170 mg/kg, i.p., o.d., 10 days) provided a T/C ratio close to 60% on day 8 after the treatment was completed. The therapeutic index-estimated as LD&lt;sub>50&lt;/sub>/ED&lt;sub>50&lt;/sub>-for compound &lt;b>29&lt;/b> in mice was ≥2.5. Molecular docking studies were carried out to predict the possible binding modes of the examined molecules towards MDM2 as the feasible biological target. However, such a mechanism was not confirmed by Western blot data and, apparently, the synthesized compounds have a different mechanism of cytotoxic action.</pubmed_abstract><journal>Molecules (Basel, Switzerland)</journal><pubmed_title>Synthesis and Biological Evaluation of Novel &lt;i>Dispiro&lt;/i>-Indolinones with Anticancer Activity.</pubmed_title><pmcid>PMC9919490</pmcid><funding_grant_id>21-13-00023</funding_grant_id><pubmed_authors>Ivanenkov YA</pubmed_authors><pubmed_authors>Ayginin AA</pubmed_authors><pubmed_authors>Shafikov RR</pubmed_authors><pubmed_authors>Serebryakova MS</pubmed_authors><pubmed_authors>Majouga AG</pubmed_authors><pubmed_authors>Beloglazkina AA</pubmed_authors><pubmed_authors>Barashkin AA</pubmed_authors><pubmed_authors>Skvortsov DA</pubmed_authors><pubmed_authors>Tafeenko VA</pubmed_authors><pubmed_authors>Kukushkin ME</pubmed_authors><pubmed_authors>Beloglazkina EK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis and Biological Evaluation of Novel &lt;i>Dispiro&lt;/i>-Indolinones with Anticancer Activity.</name><description>Novel variously substituted thiohydantoin-based &lt;i>dispiro&lt;/i>-indolinones were prepared using a regio- and diastereoselective synthetic route from 5-arylidene-2-thiohydantoins, isatines, and sarcosine. The obtained molecules were subsequently evaluated in vitro against the cancer cell lines LNCaP, PC3, HCT&lt;sup>wt&lt;/sup>, and HCT&lt;sup>(-/-)&lt;/sup>. Several compounds demonstrated a relatively high cytotoxic activity vs. LNCaP cells (IC&lt;sub>50&lt;/sub> = 1.2-3.5 µM) and a reasonable selectivity index (SI = 3-10). Confocal microscopy revealed that the conjugate of propargyl-substituted &lt;i>dispiro&lt;/i>-indolinone with the fluorescent dye Sulfo-Cy5-azide was mainly localized in the cytoplasm of HEK293 cells. P388-inoculated mice and HCT116-xenograft BALB/c nude mice were used to evaluate the anticancer activity of compound &lt;b>29&lt;/b> in vivo. Particularly, the TGRI value for the P388 model was 93% at the final control timepoint. No mortality was registered among the population up to day 31 of the study. In the HCT116 xenograft model, the compound (170 mg/kg, i.p., o.d., 10 days) provided a T/C ratio close to 60% on day 8 after the treatment was completed. The therapeutic index-estimated as LD&lt;sub>50&lt;/sub>/ED&lt;sub>50&lt;/sub>-for compound &lt;b>29&lt;/b> in mice was ≥2.5. Molecular docking studies were carried out to predict the possible binding modes of the examined molecules towards MDM2 as the feasible biological target. However, such a mechanism was not confirmed by Western blot data and, apparently, the synthesized compounds have a different mechanism of cytotoxic action.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2024-11-19T19:07:07.043Z</modification><creation>2024-11-19T19:07:07.043Z</creation></dates><accession>S-EPMC9919490</accession><cross_references><pubmed>36770991</pubmed><doi>10.3390/molecules28031325</doi></cross_references></HashMap>